TVTX vs. HROW, EPZM, OMER, RIGL, INDV, GERN, BHC, DCPH, MRVI, and AMRX
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Harrow (HROW), Epizyme (EPZM), Omeros (OMER), Rigel Pharmaceuticals (RIGL), Indivior (INDV), Geron (GERN), Bausch Health Companies (BHC), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "medical" sector.
Harrow (NASDAQ:HROW) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.
Harrow has higher earnings, but lower revenue than Travere Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
72.8% of Harrow shares are held by institutional investors. 13.7% of Harrow shares are held by company insiders. Comparatively, 4.1% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Harrow presently has a consensus price target of $28.60, indicating a potential upside of 61.22%. Travere Therapeutics has a consensus price target of $15.58, indicating a potential upside of 114.35%. Given Harrow's higher possible upside, analysts clearly believe Travere Therapeutics is more favorable than Harrow.
In the previous week, Harrow had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 5 mentions for Harrow and 4 mentions for Travere Therapeutics. Harrow's average media sentiment score of 1.39 beat Travere Therapeutics' score of 0.77 indicating that Travere Therapeutics is being referred to more favorably in the news media.
Harrow has a net margin of -22.59% compared to Harrow's net margin of -87.94%. Travere Therapeutics' return on equity of -39.82% beat Harrow's return on equity.
Harrow has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
Harrow received 29 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 56.55% of users gave Harrow an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
Summary
Harrow beats Travere Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
